Mitsue Saito

Tokyo, 1138421, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications

Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.

Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: June 13, 2026

Surgical training outcomes of female versus male surgeons in Japan.

Surgical training outcomes of female versus male surgeons in Japan.

Journal: Surgery today
Published: May 08, 2026

Timing and motivation behind the decision to become a surgeon: Gender and optimal recruitment insights.

Timing and motivation behind the decision to become a surgeon: Gender and optimal recruitment insights.

Journal: Surgery today
Published: March 20, 2026

Self-reported harassment during Japanese surgical residency: secondary analysis of a nationwide survey of newly board-certified surgeons.

Self-reported harassment during Japanese surgical residency: secondary analysis of a nationwide survey of newly board-certified surgeons.

Journal: Surgery today
Published: March 16, 2026

Correction: A nationwide questionnaire survey to investigate facility‑based disparities in satisfaction and working conditions of surgical trainees in Japan: university hospitals, community hospitals, and hybrid‑type facilities.

Correction: A nationwide questionnaire survey to investigate facility‑based disparities in satisfaction and working conditions of surgical trainees in Japan: university hospitals, community hospitals, and hybrid‑type facilities.

Journal: Surgery today
Published: November 14, 2025

Advancing patient-centred CINV care: gaps in olanzapine trial design - Authors' reply.

Advancing patient-centred CINV care: gaps in olanzapine trial design - Authors' reply.

Journal: The Lancet. Oncology
Published: September 05, 2025

Longer hours, limited returns? a post-hoc National survey analysis of overtime hours during surgical training in Japan.

Longer hours, limited returns? a post-hoc National survey analysis of overtime hours during surgical training in Japan.

Journal: Surgery today
Published: March 10, 2025

A nationwide questionnaire survey to investigate facility-based disparities in satisfaction and working conditions of surgical trainees in Japan: university hospitals, community hospitals, and hybrid-type facilities.

A nationwide questionnaire survey to investigate facility-based disparities in satisfaction and working conditions of surgical trainees in Japan: university hospitals, community hospitals, and hybrid-type facilities.

Journal: Surgery today
Published: February 13, 2025

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.

Journal: The Lancet. Oncology
Published: January 14, 2025

Regional disparity in surgical residency training and work environment between urban and regional hospitals: an additional perspective from a nationwide survey of surgical residents.

Regional disparity in surgical residency training and work environment between urban and regional hospitals: an additional perspective from a nationwide survey of surgical residents.

Journal: Surgery today
Published: December 03, 2024

Novel breast reconstruction technique using ex vivo mononuclear (RE-01) cells and adipose-derived mesenchymal stem cells.

Novel breast reconstruction technique using ex vivo mononuclear (RE-01) cells and adipose-derived mesenchymal stem cells.

Journal: Regenerative therapy
Published: October 21, 2024

Real-World Clinical Outcomes of Treatment With Olaparib for BRCA1/2 Mutation-Positive Metastatic Breast Cancer in Japanese Patients.

Real-World Clinical Outcomes of Treatment With Olaparib for BRCA1/2 Mutation-Positive Metastatic Breast Cancer in Japanese Patients.

Journal: Cureus
Published: October 14, 2024
Showing 1-12 of 106

Last Updated: 09/26/2026